Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Non-Current Deferred Tax Liability (2020 - 2025)

Bioventus (BVS) has disclosed Non-Current Deferred Tax Liability for 6 consecutive years, with $433000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 23.23% year-over-year to $433000.0, compared with a TTM value of $433000.0 through Dec 2025, down 23.23%, and an annual FY2025 reading of $433000.0, down 23.23% over the prior year.
  • Non-Current Deferred Tax Liability was $433000.0 for Q4 2025 at Bioventus, down from $786000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $159.3 million in Q4 2022 and bottomed at $351000.0 in Q2 2023.
  • Average Non-Current Deferred Tax Liability over 5 years is $36.0 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability soared 1674.27% in 2021, then crashed 99.7% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at $59.7 million in 2021, then crashed by 96.23% to $2.2 million in 2022, then fell by 8.67% to $2.1 million in 2023, then tumbled by 72.53% to $564000.0 in 2024, then decreased by 23.23% to $433000.0 in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for BVS at $433000.0 in Q4 2025, $786000.0 in Q3 2025, and $651000.0 in Q2 2025.